Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi.
Location: United States, Massachusetts, Watertown
Employees: 51-200
Total raised: $152.6M
Founded date: 2007
Investors 4
| Date | Name | Website |
| - | ND CAPITAL | nd.capital |
| - | I2BF Globa... | i2bf.com |
| - | Vivo Capit... | vivocapita... |
| - | Solasta Ve... | solasta-ve... |
Funding Rounds 6
| Date | Series | Amount | Investors |
| 01.09.2020 | - | $35M | - |
| 08.09.2015 | Series E | $38M | - |
| 15.10.2014 | - | $20M | - |
| 19.06.2014 | - | $9.35M | - |
| 27.10.2011 | - | $47.25M | - |
| 17.08.2010 | Grant | $3M | - |
Mentions in press and media 23
| Date | Title | Description |
| 02.07.2024 | Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout | Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout Tue, Jul 02, 2024 08:00 CET Report this content Sobi® today announced the initiation of a rolling Biologics Licen... |
| 21.03.2023 | Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint | Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint Tue, Mar 21, 2023 08:28 CET Report this content --Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLV... |
| 07.07.2022 | Manufacturing roundup: WuXi continues its expansion drive with another plant opening in Changzhou; Swiss biotech nets another acquisition | Managing a co-developed drug isn’t easy, particularly when you add a third-party manufacturing partner into the mix. Now, AskBio will hit the exits on a licensing deal with Selecta for gene therapy program MMA-101 after finding fault with a... |
| 06.04.2022 | Selecta Biosciences Announces $38.7 Million Underwritten Offering | WATERTOWN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta” or the “Company”), a biotechnology company focused on developing tolerogenic therapies to mitigate unwanted immune responses, today ann... |
| 10.01.2022 | Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy Capsids | WATERTOWN, Mass. and BOSTON, Jan. 10, 2022 /PRNewswire/ -- Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unw... |
| 08.11.2021 | AI upstart grabs $40M launch round; Sanofi backs a gene therapy player; Axsome hits a snag at the FDA | Boston AI-focused biotech DeepCure closed a $40 million Series A, according to a company announcement this morning — adding more than five times the amount of money the company had before: from $7 million raised since the co... |
| 26.10.2021 | Selecta Biosciences and Ginkgo Bioworks Announce Partnership to Advance Treatments for Orphan and Rare Diseases | BOSTON and WATERTOWN, Mass., Oct. 26, 2021 /PRNewswire/ -- Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unw... |
| 09.09.2021 | Seattle startup Cyrus inks protein-design deal with immune biotech Selecta worth up to $1.5 billion | Cyrus Biotechnology has several drug discovery and development partnerships and also sells Cyrus Bench, a software platform for protein engineering. (Cyrus Photo) Seattle-based Cyrus Biotechnology is entering a protein engineering collabora... |
| 01.09.2020 | Selecta Biosciences Secures Up To $35 Million Debt Financing | WATERTOWN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmT... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
Show more